Abstract Details

Title Patient Treatment Satisfaction with OnabotulinumtoxinA Versus Topiramate for Chronic Migraine

Topic Headache

Presentation(s) P1 - Poster Session 1 (8:00 AM-9:00 AM)

Poster/Presentation
Number 15-009

Objective To describe patient treatment satisfaction (PTS) with onabotulinumtoxinA versus topiramate for chronic migraine (CM).

Background FORWARD (NCT02191579) evaluated the comparative effectiveness (blend of efficacy and tolerability) and safety of onabotulinumtoxinA and topiramate in individuals with CM. FORWARD demonstrated that onabotulinumtoxinA had greater clinical utility than topiramate based on primary and secondary endpoints.

Design/Methods FORWARD was a US, multicenter, randomized, parallel-group, open-label, prospective study. Adults (18-65 years) with CM (≥15 headache days/month) were randomized to 155 U of onabotulinumtoxinA for 3 treatment cycles or up to 50-100 mg/day of topiramate. The PTS questionnaire, which measured overall treatment satisfaction and satisfaction based on headache frequency, headache severity, and ability to perform daily activities, was completed by participants at weeks 6, 18, and 30. Each question was rated on a 5-point Likert scale (extremely satisfied to extremely dissatisfied). The proportions of participants recommending their treatment was evaluated.

Results 282 participants were enrolled (onabotulinumtoxinA, n=140; topiramate, n=142). Higher proportions of participants receiving onabotulinumtoxinA versus topiramate reported overall satisfaction at week 6 (55.7% vs 28.2%), week 18 (65.0% vs 17.6%), and week 30 (59.3% vs 16.2%). Similar trends were observed for satisfaction with reduction in headache frequency (week 6: 55.7% vs 31.6%; week 18: 62.9% vs 17.6%; week 30: 59.3% vs 16.2%), headache severity (week 6: 54.2% vs 30.9%; week 18: 61.5% vs 19.0%; week 30: 57.1% vs 15.5%), and ability to perform daily activities (week 6: 59.3% vs 31.0%; week 18: 62.8% vs 18.3%; week 30: 59.3% vs 16.9%). More participants would recommend onabotulinumtoxinA versus topiramate (week 6: 60.0% vs 44.4%; week 18: 75.7% vs 19.7%; week 30: 67.1% vs 16.9%).

Conclusions OnabotulinumtoxinA treatment was associated with higher treatment satisfaction and willingness to recommend treatment than topiramate. Results are consistent with overall study findings where onabotulinumtoxinA had greater effectiveness (higher efficacy and tolerability) and clinical utility than topiramate.

Authors/Disclosures
Tsz (Tiffany) Chan, PharmD, BCPS (AbbVie) PRESENTER	Dr. Chan has received personal compensation for serving as an employee of AbbVie. Dr. Chan has or had stock in AbbVie.
Andrew M. Blumenfeld, MD, FAAN (Cedars Sinai)	Dr. Blumenfeld has received personal compensation for serving as an employee of The Los Angeles Headache Center. Dr. Blumenfeld has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Allergan/Abbvie. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Best Doctors. Dr. Blumenfeld has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Guidepoint. Dr. Blumenfeld has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GLG. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Theranica. Dr. Blumenfeld has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Aeon. Dr. Blumenfeld has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Revance. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lilly. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Blumenfeld has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Lundbeck. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Blumenfeld has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Axsome. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Axon. Dr. Blumenfeld has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Cedar Sinai. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Blumenfeld has received personal compensation in the range of $100,000-$499,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Aeon. Dr. Blumenfeld has received personal compensation in the range of $100,000-$499,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Revance. Dr. Blumenfeld has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theranica. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Axsome. Dr. Blumenfeld has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for Allergan/Abbvie. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amgen. Dr. Blumenfeld has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Teva. Dr. Blumenfeld has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Lilly. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biohaven. Dr. Blumenfeld has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Lundbeck. Dr. Blumenfeld has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for AXSOME.
Tae Jin Park (AbbVie)	Mr. Park has received personal compensation for serving as an employee of AbbVie. Mr. Park has stock in AbbVie.
Iryna Shakhmantsir (Abbvie)	Dr. Shakhmantsir has received personal compensation for serving as an employee of AbbVie.
John F. Rothrock, MD (Inova Health)	Dr. Rothrock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Rothrock has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for AbbVie. Dr. Rothrock has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Lundbeck. The institution of Dr. Rothrock has received research support from AbbVie. The institution of Dr. Rothrock has received research support from Ipsen. The institution of Dr. Rothrock has received research support from Lundbeck.

��ɫ��

��ɫ��